PennyStockPayCheck.com Rss

Featured Posts

Chase Bank Limits Cash Withdrawals, Bans International... Before you read this report, remember to sign up to http://pennystockpaycheck.com for 100% free stock alerts Chase Bank has moved to limit cash withdrawals while banning business customers from sending...

Read more

Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...

Read more

Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday

Read more

Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...

Read more

UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...

Read more

The FDA has approved Roche’s (RHHBY.PK) Perjeta drug for treating metastatic breast cancer in patients who have a certain gene mutation. Roche hopes Perjeta will be available within two weeks, although the FDA says there are production issues that…

Category : Stocks

The FDA has approved Roche’s (RHHBY.PK) Perjeta drug for treating metastatic breast cancer in patients who have a certain gene mutation. Roche hopes Perjeta will be available within two weeks, although the FDA says there are production issues that could hamper supply. Analysts forecast that the drug could generate annual sales of $1.6B by 2016. Post your comment!

More: The FDA has approved Roche’s (RHHBY.PK) Perjeta drug for treating metastatic breast cancer in patients who have a certain gene mutation. Roche hopes Perjeta will be available within two weeks, although the FDA says there are production issues that…

Penny Stock Picks

Post to Twitter

Post a comment